The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
Author: Benzinga Newsdesk | September 04, 2024 09:03am
CEL-SCI Corporation (NYSE:CVM) today reported it has received a decision letter from the United Kingdom's Healthcare Products Regulatory Agency (MHRA) granting Multikine (Leukocyte Interleukin, Injection)* a product specific waiver for the treatment of head and neck cancer in a pediatric population of people up to 18 years of age. As a result, CEL-SCI will not be required to evaluate Multikine in a pediatric population as part of license and marketing clearance review in the UK.
Posted In: CVM